Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The cervical cancer (CC) market was valued at $607 million in the 8 major markets (8MM) in 2020. The market is projected to grow at a CAGR of more than 22% during the forecast period.

The cervical cancer market report provides an overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It includes a 10-year epidemiological forecast for diagnosed incident cases of CC. The diagnosed incident cases of CC are further segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) in these markets.

Cervical cancer market overview

Cervical cancer market overview

For more insights on this report, download a free sample

What are the market dynamics in the cervical cancer market?

Chronic infection with high-risk oncogenic subtypes of the human papillomavirus (HPV) is the main etiological factor in cervical carcinogenesis, with HPV infection detected in almost all CC cases (Senapati, Senapati and Dwibedi, 2016). HPV infection of the cervix is primarily contracted via sexual intercourse. HPV 16 and 18 are the most common HPV sub-types leading to CC.

The most common subtypes of CC are squamous cell carcinomas, which arise from the squamous cells that cover the outer surface of the cervix (ectocervix). Adenocarcinomas arise from the glandular cells that are scattered along the endocervical canal (inner surface of the cervix). Patients can present with both squamous and glandular cancer cells, giving rise to a diagnosis of adenosquamous carcinomas.

What are the key age segments in the cervical cancer market?

The cervical cancer market can be segmented by age into 18-29 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60- 69 years, 70-79 years, and above 80 years.

In 2020, for the 8MM combined, adults ages 40-49 years contributed the highest proportion of the diagnosed incident cases of CC. In the US, Italy, Spain, Japan, and urban China, the peak diagnosed incident cases of CC by age occurred in ages 40-49 years. In France and Germany, the peak diagnosed incident cases occurred in ages 50-59 years, and in the UK, the peak diagnosed incident cases occurred in ages 30-39 years. In France, Germany, Italy, Spain, Japan, and urban China, the diagnosed incident cases of CC were lowest in ages 18-29 years, and in the US and the UK, cases were lowest in ages 80 years and older. In the 8MM, urban China had the highest diagnosed incident cases of CC in ages 40-49 years with 23,716 cases, and the lowest diagnosed incident cases of CC were in Spain in ages 18-29 years with 35 cases. This difference in age-specific cases might be driven by the underlying population trends in the countries.

Cervical cancer market, by age

Cervical cancer market, by age

For more age segment insights, download a free sample

What are the key stages in the cervical cancer market by FIGO?

The cervical cancer market by FIGO can be segmented by stage into stage IA, stage IB1-2, stage IB3, stage IIA1, stage IIA2, stage IIB, stage III, stage IVA, and stage IVB. In the 8MM, the highest number of diagnosed incident cases of CC was in stages IB1-2, followed by stage IA, and stage IIB.

Cervical cancer market, by stage

Cervical cancer market, by stage

For more stage insights, download a free sample

Which are the eight major markets of cervical cancer?

The eight major markets (8MM) of cervical cancer include the US, France, Germany, Italy, the UK, Spain, Japan, and China. In 2020, the diagnosed incidence of CC was highest in urban China, followed by Japan, and Germany, and was lowest in the US. The rate of increase was highest in urban China.

Cervical cancer market, by 8 major markets

Cervical cancer market, by 8 major markets

For more 8 major market insights, download a free sample

Which are the key companies in the cervical cancer market?

Some of the key companies in the cervical cancer market are ADC therapeutics, Agenus, Akeso Biopharma, AstraZeneca, Betta Pharmaceuticals, Biocad, Bristol Myers Squibb, Exelixis, Genentech (Roche), and Genmab.

Cervical cancer market, by key companies

Cervical cancer market, by key companies

To know more about key companies, download a free sample

Market Report Scope

Market size 2020 $607 million
CAGR >22%
Key age segments 18-29 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60- 69 years, 70-79 years, and above 80 years
Key stages Stage IA, Stage IB1-2, Stage IB3, Stage IIA1, Stage IIA2, Stage IIB, Stage III, Stage IVA, And Stage IVB
8 major market (8MM) The US, France, Germany, Italy, the UK, Spain, Japan, and China
Key companies ADC therapeutics, Agenus, Akeso Biopharma, AstraZeneca, Betta Pharmaceuticals, Biocad, Bristol Myers Squibb, Exelixis, Genentech (Roche), and Genmab

 

Scope

  • Overview of cervical cancer including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline cervical cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting cervical cancer therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III).
  • Analysis of the current and future market competition in the global cervical cancer therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated approval and launch of 13 pipeline therapies, the approval of an agent currently marketed in the US across the remaining 7MM, and the label expansion of one currently marketed therapy across the 8MM during the forecast period.

The main barriers to growth in the 8MM are patent expiries including those of Avastin, Keytruda, Imfinzi and Tecentriq.

Among the late-stage pipeline products and marketed agents, immunotherapies are expected to dominate, however Tivdak is expected to be the market leading brand.

The most important unmet needs in the cervical cancer market include: the need for adjuvant therapy in the locally advanced setting, the need for novel agents other than immunotherapies, the need for approval of agents outside the US market, the need for fertility-sparing treatment options, and an increase in HPV vaccine uptake.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global cervical cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cervical cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter- strategies to gain a competitive advantage.
  • Track drug sales in the global cervical cancer therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

ADC therapeutics
Agenus
Akeso Biopharma
AstraZeneca
Betta Pharmaceuticals
Biocad
Bristol Myers Squibb
Exelixis
Genentech (Roche)
Genmab
Innovent Biologics
Iovance Biotherapeutics
ISA Pharmaceuticals
Jiangsu HengRui Medicine
Merck & Co.
Mersana Therapeutic
Ono Pharmaceutical
Qilu Pharmaceutical
Regeneron
RemeGen
Sanofi
Seagen
Shanghai Henlius Biotech
Shanghai Miracogen
Shanghai Pharmaceuticals
Synaffix

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Cervical Cancer: Executive Summary

1.1 The CC Market Will Expand to $4.8 Billion in 2030

1.2 Seagen and Genmab Expected to Take Market-Leading Position in 2030

1.3 Approval of Checkpoint Inhibitors and Tivdak Will Partially Address Significant Unmet Needs

1.4 Immunotherapy to Become Leading Therapy Class

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of CC (ICD-10 = C53)

4.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of CC by International Federation of Gynecology and Obstetrics Stage at Diagnosis

4.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of CC by Histology Subtypes

4.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of CC by Biomarkers

4.4.7 Forecast Assumptions and Methods: Diagnosed Incident Cases of CC by Human Papillomavirus Status

4.4.8 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of CC

4.5 Epidemiological Forecast for CC (2020–30)

4.5.1 Diagnosed Incident Cases of CC

4.5.2 Age-Specific Diagnosed Incident Cases of CC

4.5.3 Diagnosed Incident Cases of CC by International Federation of Gynecology and Obstetrics Stage at Diagnosis

4.5.4 Diagnosed Incident Cases of CC by Histology Subtypes

4.5.5 Diagnosed Incident Cases of CC by Biomarkers

4.5.6 Diagnosed Incident Cases of CC by Human Papillomavirus Status

4.5.7 Five-Year Diagnosed Prevalent Cases of CC

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.1.1 US

5.1.2 5EU

5.1.3 Japan

5.1.4 China

5.2 KOL Insights on Disease Management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of Fertility-Sparing Options for Patients in Early Disease Setting

7.3 Lack of Adjuvant Therapy in the Locally Advanced Setting

7.4 Lack of Approval for Agents Outside the US

7.5 The Need for Novel Treatments Other than Immunotherapy

7.6 An Increase in HPV Vaccine Uptake

8 R&D Strategies

8.1 Overview

8.1.1 Expansion of Effective Therapies into Earlier Lines of Treatment

8.1.2 Combination Immune Checkpoint Inhibition

8.1.3 Development of ADCs

8.2 Clinical Trials Design

8.2.1 Duration of Immune Checkpoint Maintenance Therapy in the Locally Advanced Setting

8.2.2 The Exclusion of Immune Checkpoint Inhibitor-Exposed Patients from Second-Line Trials

8.2.3 Exclusion of HIV-Positive Patients

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 China

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Epidemiology Reviewers

13.6.6 Vice President of Disease Analysis and Intelligence

13.6.7 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: CC: Key Metrics in the 8MM

Table 2: Pathologic Staging of CC Using FIGO Classification

Table 3: Risk Factors and Comorbid Conditions Associated with CC

Table 4: 8MM, Diagnosed Incident Cases of CC by FIGO Stage at Diagnosis, Women, Ages ≥18 Years, N, 2020

Table 5: 8MM, Diagnosed Incident Cases of CC by HPV Status, Women, Ages ≥18 Years, N, 2020

Table 6: Treatment Guidelines for CC

Table 7: Top 10 Deals by Value, 2018–21

Table 8: CC Market – Global Drivers and Barriers, 2020–30

Table 9: Key Events Impacting Sales for CC in the US, 2020–30

Table 10: CC Market – Drivers and Barriers in the US, 2020–30

Table 11: Key Events Impacting Sales for CC in the 5EU, 2020–30

Table 12: CC Market – Drivers and Barriers in the 5EU, 2020–30

Table 13: Key Events Impacting Sales for CC in Japan, 2020–30

Table 14: CC Market – Drivers and Barriers in Japan, 2020–30

Table 15: Key Events Impacting Sales for CC in China, 2020–30

Table 16: CC Market – Drivers and Barriers in China, 2020–30

Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for CC in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in CC During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Locally Advanced CC During the Forecast Period

Figure 4: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the First-Line Treatment of Persistent, Recurrent, or Distally Metastatic CC During the Forecast Period

Figure 5: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Second-Line Treatment of Persistent, Recurrent, or Distally Metastatic CC During the Forecast Period

Figure 6: HPV Oncogenes Drive Malignant Transformation of Cervical Cells

Figure 7: 8MM, Diagnosed Incidence of CC (Cases per 100,000 population), Women, Ages ≥18 Years, 2010–30

Figure 8: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CC

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CC by FIGO Stage at Diagnosis

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CC by Histology Subtypes

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CC by Biomarkers and HPV Status

Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CC

Figure 13: 8MM, Diagnosed Incident Cases of CC, N, Women, Ages ≥18 Years, 2020

Figure 14: 8MM, Diagnosed Incident Cases of CC by Age, N, Women, 2020

Figure 15: 8MM, Diagnosed Incident Cases of CC by Histology Subtypes, N, Women, Ages ≥18 Years, 2020

Figure 16: 8MM, Diagnosed Incident Cases of CC by Biomarkers, N, Women, Ages ≥18 Years, 2020

Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of CC, N, Women, Ages ≥18 Years, 2020

Figure 18: Treatment Paradigm for CC

Figure 19: Unmet Needs and Opportunities in CC

Figure 20: Overview of the Development Pipeline in CC

Figure 21: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for CC in the 8MM During the Forecast Period

Figure 22: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC, Platinum Chemoradiation for the Treatment of Locally Advanced Disease

Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC, Avastin + Chemotherapy for Treatment of Persistent, Recurrent, or Distally Metastatic Disease – First Line

Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC, Keytruda for Treatment of Persistent, Recurrent, or Distally Metastatic Disease – Second Line

Figure 25: Analysis of the Company Portfolio Gap in CC During the Forecast Period

Figure 26: Global (8MM) Sales Forecast by Country for CC in 2020 and 2030

Figure 27: Sales Forecast by Class for CC in the US in 2020 and 2030

Figure 28: Sales Forecast by Class for CC in the 5EU in 2020 and 2030

Figure 29: Sales Forecast by Class for CC in Japan in 2020 and 2030

Figure 30: Sales Forecast by Class for CC in China in 2020 and 2030

Frequently asked questions

Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 in real time.

  • Access a live Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.